Health News Releases

  • Today August 23
November 26, 2019 10:09
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patien
November 26, 2019 09:11
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in
November 25, 2019 13:44
Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients
Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient S
November 22, 2019 11:21
PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies, today announced a multimillion dollar agreement between its wholly-owned subsidiary APS Bio
November 18, 2019 14:00
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding
November 18, 2019 10:41
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas
November 15, 2019 11:37
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strat
November 14, 2019 06:00
College of American Pathologists and Seoul National University Host Advanced Education for Doctors and Laboratory Scientists
In an effort to foster laboratory quality and further advance the evolving field of clinical microbiology, the College of American Pathologists (CAP), in partnership with Seoul National University Col
November 13, 2019 10:38
Cook Medical’s Leadership Updates in Asia-pacific Reinforce Focus on Growth and Physician Relationships
Cook Medical announced today that Jean-Marc Creissel has been named vice president and director of Asia-Pacific. In his new role, Creissel will lead the Asia-Pacific teams to transform Cook Medical
November 13, 2019 10:00
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whet
November 12, 2019 17:56
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the c
November 12, 2019 10:45
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meetin
November 11, 2019 11:09
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance R&D Across Two Separate Programs for Oncology
Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclica’s proprietary AI-integ
November 11, 2019 09:55
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in p
November 08, 2019 16:35
Phase 3 Trial of NINLARO™ (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The tri
November 08, 2019 14:38
FIND Collaborates with SpeeDx and QuantuMDx
SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery
November 07, 2019 19:36
Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®
Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) tech
November 07, 2019 18:41
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that results from the primary endpoint analysis of the ongoing pivotal Phase 3 Tetravalent Immunization against Den
November 07, 2019 16:14
Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003. The Singe
November 07, 2019 15:48
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11
November 06, 2019 18:02
Octapharma’s fibryga® Receives European Label Extension to Treat Acquired Fibrinogen Deficiency (AFD)
Octapharma announced today that the human fibrinogen concentrate fibryga® has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval exte
November 06, 2019 16:01
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to deve
November 05, 2019 16:14
Takeda Continues Strategic Divestitures With Sale of Select OTC and Non-Core Assets to STADA for $660 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”),
November 04, 2019 16:23
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191030006224/en/ Underl
November 01, 2019 18:06
The Mary Kay Foundation Awards $3.1 Million in Cancer Research and Domestic Violence Shelter Grants
The Mary Kay FoundationSM recently awarded over $3 million in cancer research and domestic violence shelter grants around the country. The Mary Kay Foundation was established in 1996 with the overarch
25 per page50 per page75 per page100 per page